Finn
IOVA Biotechnology · Cell therapy · Oncology · Commercial stage · Thesis updated November 8, 2026

Amtagvi revenue crosses $100 million as margin hits 60%

01 Running thesis

A real launch gaining speed

Iovance is moving past its early launch growing pains. Amtagvi demand is strong, with management reporting over $100 million in Q3 2026 Amtagvi revenue. That number proved the market needs the product and pushed total revenue to $122 million. The company is now verging on profitability, with earnings per share losses narrowing to just $0.05.

The bull case is that Iovance owns a first mover position in tumor infiltrating lymphocyte therapy, often called TIL therapy. In plain English, doctors take immune cells from a patient's tumor, grow them outside the body, then put them back to attack the cancer. The gross margin reaching 60% in Q3 2026 shows the internal factory can run efficiently as volume grows.

The bear case is that this is still hard medicine to make and sell, and international expansion is taking time. Ex-U.S. approvals in the UK and Europe are pending, and setting up international reimbursement is a slow process.

The next proof points are clear: securing UK and Swissmedic approvals in early 2027, finalizing the NSCLC trial dataset for a 2027 submission, and progressing the new POSITILITY biomarker cohort.

Nov 2026▲Q3 2026 results showed massive commercial momentum. Amtagvi revenue crossed $100 million, gross margins expanded to 60%, and cash runway was extended into 2029.
Aug 2026▲Q2 2026 results showed strong momentum. Amtagvi revenue hit $91 million, gross margin recovered to a record 56%, and cash runway was extended into the second half of 2028.
May 2026▲Q1 2026 results strengthened the launch case. Iovance guided Q2 Amtagvi revenue to $79 million to $81 million and full-year 2026 total revenue to $350 million to $370 million, while extending cash runway into 2028.
May 2026▼The same update added execution concerns. Gross margin fell to 41% because of facility costs, the UK MAA was withdrawn with a planned 2026 resubmission, and ATM equity use remained a dilution risk.
May 2026▲Pipeline optionality improved. Iovance reported a 40% confirmed response rate in metastatic serous endometrial cancer, started a sarcoma registrational trial, and named IOV-3001 as a next-generation IL-2 candidate.
Feb 2026▲Iovance completed its shift to internal iCTC manufacturing and reported a 50% gross margin in Q4 2025. The company also received FDA fast-track designation for the NSCLC program.
Feb 2026▲The 2025 Form 10-K added real-world support for Amtagvi, with a 44% physician-assessed response rate and a 73% disease control rate in the first retrospective study.
Nov 2025▲Q3 2025 showed stronger commercial footing, with $67.45 million in total product revenue and more than 80 Authorized Treatment Centers. The move toward internal manufacturing reduced outside production risk.
02 Business model

A custom therapy factory

Iovance makes money from Amtagvi, its FDA-approved personalized TIL therapy for advanced melanoma, and Proleukin, an IL-2 drug used with the treatment. Each Amtagvi treatment is made from a specific patient's tumor cells, making this closer to a custom factory than a normal drug plant.

The company says its moat is the 22-day Gen 2 manufacturing process and the internal Iovance Cell Therapy Center in Philadelphia, also called iCTC. Centralizing production there helped gross margin reach 60% in Q3 2026. The facility will also handle international commercial launches without the need for overseas plants.

Proleukin is tied to Amtagvi use. Iovance expects treatment centers to use about 15 Proleukin vials per Amtagvi infusion, and Proleukin sales can lead Amtagvi infusions by 2 to 3 months. That makes Proleukin a useful demand signal, not just a separate product.

To reach more patients, Iovance is adding specialty pharmacy distribution, including McKesson Biologics. The network has grown to over 100 active treatment centers, with community hospitals making up over a third of the total.

03 Product portfolio

Amtagvi plus bigger bets

Growth engine

Amtagvi

Amtagvi, also called lifileucel, is the main product and is FDA-approved for advanced melanoma. It is also approved in Australia and Canada.

Steady

Proleukin

Proleukin, or aldesleukin, is used as part of the Amtagvi treatment regimen. Iovance expects about 15 vials per Amtagvi infusion.

Option

NSCLC lifileucel program

Iovance is studying lifileucel in previously treated non-small cell lung cancer. The program targets a 2027 submission and includes a biomarker cohort showing a 59.1% response rate.

Option

Sarcoma lifileucel program

A registrational trial is underway in advanced sarcomas. The company aligned with the FDA on a potential accelerated pathway targeting a 2028 or 2029 submission.

Option

Endometrial cancer program

Iovance reported a 40% confirmed objective response rate for lifileucel in metastatic serous endometrial cancer. More data are needed before this becomes a commercial product.

Option

IOV-5001 and IOV-3001

IOV-5001 is an IL-12-tethered TIL therapy with a clinical trial underway. IOV-3001 is a next-generation IL-2 candidate meant to improve dosing.

04 Business segments

One segment, two revenue lines

Amtagvi82%growing fast
Proleukin18%modest

Iovance reports as one operating segment. The mix below uses Q3 2026 results: Amtagvi revenue of over $100 million inside total revenue of $122 million.

05 Risk factors

What could go wrong

Manufacturing does not scale cleanly

High impact · Medium odds

Amtagvi is made from each patient's own tumor cells. That makes quality, timing, and raw materials harder to control than a normal drug. Gross margin hit 60% in Q3 2026, but the company must maintain that efficiency as volume grows.

We watchManufacturing turnaround time, out-of-spec rates, and quarterly gross margin numbers.

Pipeline data fail to expand the market

High impact · Medium odds

The long-term upside depends on moving TIL therapy beyond melanoma. NSCLC, sarcoma, and endometrial cancer could make the market much bigger. Weak response data or slow enrollment would leave Iovance dependent on melanoma.

We watchNSCLC clinical updates, POSITILITY cohort enrollment, and sarcoma trial progress.

Ex-U.S. approvals take longer

Medium impact · Medium odds

Australia and Canada approved Amtagvi, but Europe and the UK remain pending. Iovance resubmitted its UK application in July 2026 and expects a decision in early 2027. Delays push back international revenue.

We watchUK and Swissmedic review timelines and any request for more clinical evidence.
06 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Iovance Q3 2026 earnings transcript
  2. Iovance Q2 2026 Form 10-Q
  3. Iovance Q1 2026 earnings transcript
07 Explore the industry

Comparable Biotechnology companies

Companies near Iovance Biotherapeutics, Inc. in Finn's Biotechnology industry ranking.

Get started with Finn today